Abstract
The human immunodeficiency virus (HIV) persists in latently infected CD4+T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS.
1 Introduction
The human immunodeficiency virus (HIV), a positive RNA virus with a single strand, has two subtypes, HIV-1 and HIV-2. In 1981, HIV-1 was identified in young homosexual males. M (major), O (outlier), N (non-M, non-O), and the most recent group P, are the four groups identified. Group M viruses are further subdivided into nine subtypes (A-D, F-H, J, and K) (Bbosa et al., 2019). The HIV-1 subtype is associated with acquired immunodeficiency syndrome (AIDS) pathogenesis and progression. Total HIV-1 DNA level is a significant predictor of progression to AIDS. In vivo, higher HIV-1 DNA levels were detected in patients infected with the recombinant HIV-1 strain (CRF01_AE), which means more pathogenic (Lyu et al., 2020). Extending the scope of whole-genome sequencing to enable the correct classification of recombinant viruses is vital for AIDS diagnosis, anti-retroviral therapy, and the development of vaccines.
Three structural genes (Gag, Pol, and Env) and six regulatory genes comprise HIV-1 (Tat, Nef, Vif, Rev, Vpr, and Vpu). Env encodes gp160, which is intracellularly broken into gp120 and gp41 by the host protease (Frankel and Young, 1998). Gag proteins competitively recognize viral RNA (vRNA) packaging signals and form dimers with vRNA, which is degraded into pieces by virus proteases to produce capsid protein (CA) (shown in Figure 1) (Rein, 2019). HIV infects human CD4+T cells and damages the individual’s immune defense system. HIV-1 life cycle regulation depends on stage-specific HIV-1 gene expression. Specifically, Tat expressed early in viral infection accelerates the expression of viral genes. Simultaneously, Rev proteins play a crucial role in the transition from the early to the late stages of the HIV-1 life cycle, and they need to be degraded promptly after accomplishing their duty. Simultaneously, HIV-1 gene expression is influenced by the ubiquitin-proteasome system (UPS), which affects the HIV-1 life cycle (Rojas and Park, 2019). Initially, the viral surface protein gp120 attaches to the host cell surface receptor CD4. Under the influence of the C-C chemokine receptor type 5 (CCR5, R5) or CX-C chemokine receptor type 4 (CXCR4, X4), conformational changes lead to the exposure of gp41, which facilitates the fusion of the virus and host cell membranes. The virus then infects the host, releasing the genome for RNA replication (Rojas-Celis et al., 2019). Nef enhances HIV-1 infectivity by down-regulating the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) (Usami et al., 2015). Consequently, we expected that SERINC3 and SERINC5 would be crucial HIV diagnostic and therapeutic targets (Cano-Ortiz et al., 2023). In the early stages, some viruses reproduce explosively, triggering an immune response that reduces viral quantities in the blood. Unique to HIV infection, the virus reproduces continuously and chronically throughout time, transitioning from acute to chronic (Fauci et al., 1996). Moreover, HIV-1 viruses can be transferred through cell-to-cell contact, evading extracellular innate and adaptive immune systems (Pedro et al., 2019).
FIGURE 1
2 Single-ingredient drugs for anti-HIV
The objective of treating AIDS at this stage is to suppress viral replication maximally in patients and enable them to rebuild and sustain immune function to combat non-AIDS-related disorders. In addition to antiviral medication, comprehensive AIDS treatment stresses supportive therapy and the restoration or improvement of immunological function. It also prevents consequences like cancer and opportunistic infections. According to the specific targets of antiviral medication action, antiviral medications are categorized as follows: drugs to block viral entry (including fusion inhibitors, CD4 adhesion inhibitors, and CCR5 inhibitors), antiretroviral medications (including nucleoside and non-nucleoside reverse transcriptase inhibitors), protease inhibitors, integrase inhibitors, and coat protein inhibitors. Highly active antiretroviral therapy (HAART), or ‘cocktail’ therapy (Lu et al., 2018), refers to the combination of two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor or protease inhibitor (shown in Figure 2). Moreover, gene editing has significantly affected HIV/AIDS prevention and treatment (Zhang et al., 2022).
FIGURE 2
2.1 Blocking viruses entry cells
Class I fusion protein Envelope glycoprotein (Env) is expressed on HIV surfaces and attacks CD4+T cells, macrophages, and monocytes. It enhances the attachment of viral particles to target cells and the fusion of viral and target cell membranes. It comprises three identical glycoprotein precursors, gp160, split into two subunits: the surface glycoprotein gp120 (SU) and the transmembrane structural domain gp41 (TM), during transit to the cell surface. The gp41 has a similar structure to the fusion-mediated component of all class I fusion proteins, with the fusion peptide located at the N-terminal end and the C-terminal end lodged in the virus membrane. During infection, the engagement of the gp120 receptor binding domain with the CD4 cell receptor initiates a sequence of conformational changes in the envelope protein. This triggers gp120 dissociating from gp41, exposing and refolding gp41, and promoting membrane fusion. Furthermore, chemokine receptors such as CCR5 and CXCR4 are required for viral entry. HIV entrance inhibitors are broadly categorized into three groups: fusion inhibitors targeting gp120 and gp41, CD4 adhesion inhibitors, and chemokine receptor inhibitors (Siegert et al., 2006).
2.1.1 Fusion inhibitors
Enfuvirtide (ENF, T20) was the first HIV entrance inhibitor to authorization (Alaofi, 2022). Similar to the C-terminal repeat region (CHR) of gp41, it is called an analog, and blocks the interaction between the highly conserved region N-heptad repeat (NHR) and the gp41 CHR region in the pre-capillary intermediate (PHI), then prevents the synthesis of gp41 6-HB (CHR and NHR folding) (Monteiro et al., 2021). Residue E143 of the T20 peptide plays an essential role in the conformational structure of the peptide, and the E143A mutation affects not only the conformation of the T20 peptide but also its binding interactions with the HIV-1 receptor. This discovery has significant ramifications for optimizing and developing HIV-1 inhibitor peptides (Alaofi, 2022). Adonis Rubio et al. created D5-AR mutants based on monoclonal antibodies and the antiviral mechanism of ENF. These mutants enhance antiviral activity and support a vaccine strategy against PHI by eliciting antibodies against gp41 NHR (Rubio et al., 2021).
The conventional ENF target delivery system is susceptible to difficulties, such as a lack of specificity or inadequate medication delivery without the stimulus. To refine this technology, Taj Yeruva et al. constructed a peptide sequence as a stimulant reaction molecule directly attached to a polyethylene glycol (PEG)-based hydrogel matrix to permit proteolysis via enzyme stimulation. It protects women against HIV-1 infection (Yeruva and Lee, 2022). Tiago Figueira et al. postulated that a nanocarrier consisting of large unilamellar vesicles (LUVs) might be utilized to transport two HIV-1 inhibitors, ENF and protoporphyrin IX (PPIX), in combination. ENF and PPIX are, respectively, fusion and attachment inhibitors whose intrinsic lipophilicity results in their spontaneous incorporation into the lipid bilayer of the LUVs nanocarrier, hence boosting the synergistic action of the entering inhibitor (Figueira et al., 2020). Long-acting efavirenz-enfuvirtide co-loaded polymer-lipid hybrid nanoparticles (EFA-ENF-PLN) enabled a slow and sustained release of the two drugs from the polymer-lipid hybrid nanoparticles (PLN), and coumarin-6-loaded PLN contributed to the fight against the HIV-1 virus by increasing the uptake by T cells and macrophages (Surve et al., 2020).
Albuvirtide (ABT) is a 3-methyl imidazole (MPA)-modified HIV fusion inhibitor peptide that irreversibly binds to serum albumin and has a long half-life and potent anti-HIV activity in vivo. ABT can establish a stable α-helical conformation with the target sequence and inhibit, in a dominant-negative manner, the creation of a fused active hexa-helix bundle (6-HB), thus preventing HIV-1 Env-mediated membrane fusion and viral entry. ABT demonstrates potent inhibitory effects against HIV subtypes A, B9, and C, which dominate the global epidemic. It also inhibits the recombinant subtypes CRF07_BC and CRF01_AE. Moreover, ABT was particularly effective against HIV-1 strains resistant to T20 (Chong et al., 2012).
The gp120-binding inhibitor, fostemsavir, was approved in July 2020. As a novel HIV-1 inhibitor, it is particularly beneficial for regulating viral levels in HIV-1-infected persons with extensive therapy experience (Wang et al., 2021). Temesavir decreases gp120-mediated immunomodulatory activity, including the elimination of antibody-dependent cytotoxicity (ADCC) in uninfected bystander CD4+T cells, as well as gp120-induced cytokine bursts in peripheral blood mononuclear cells (PBMCs), implying that Fostemsavir may provide clinical benefits beyond blocking viral entry (Richard et al., 2023).
2.1.2 Attachment of CD4 to inhibitors
Ibalizumab was the first monoclonal antibody approved for treating HIV-1 infection, and it played a significant role in HIV treatment (Blair, 2020). Rather than altering HIV gp120 function with domain 1, stereotactic interference prevents gp120 from attaching to CD4. It binds to CD4 receptor domain two and does not induce immunosuppression (Bettiker et al., 2018). It is a valuable and urgent therapeutic option for individuals with multimedication-resistant HIV-1 infection (Blair, 2020); however, it carries the risk of hepatitis B virus reactivation (Kaplan et al., 2021).
A unique class of HIV-1 entry inhibitors, called peptide triazoles (PTs), can be doubly combined with CD4 receptors and co-receptor binding sites of the gp120 subunit of Env. This binding triggered a significant conformational rearrangement of Env, which in turn inactivates Env and enhanced exposure to essential and conserved neutralizable regions of gp41, providing new ideas for vaccine development (Carter et al., 2023).
2.1.3 Co-receptor inhibitors
HIV-1 should connect to the host cell’s surface and bind to CD4 to enter host cells. During this phase, the gp120 V3 loop is accessible, and HIV-1 interacts with synergistic receptors. Different cytophilic viruses determine whether they bind CCR5, CXCR4, or both, depending on differences in charge distribution and stereotaxis due to residual replacement (Tan et al., 2013). During an infection, R5-tropic viruses dominate. The gp120-gp41 complex undergoes enormous conformational changes, creating a trimeric hairpin structure that unites the viral envelope with the host cell membrane (Zhang et al., 2020).
CCR5 is a G-protein-coupled receptor (GPCR) that regulates natural killer cells (NK) and regulatory T cells (Treg). CCR5Δ32 is the most researched genetic variant of the CCR5 gene, influencing nonviral illnesses and HIV protection (Ellwanger et al., 2020). It has been demonstrated that CCR5 activation inhibits neuronal CREB and MAPK activity and axonal rejuvenation following neuronal damage. Without neuroinflammation, a direct connection between the gp120 V3 domain and CCR5 impairs synaptic plasticity and reduces memory (Riviere-Cazaux et al., 2022). Maraviroc (MVC) is a CCR5 antagonist that prevents the interaction between HIV-1 gp120 and CCR5 by binding specifically to the CCR5 receptor. MVC, the first CCR5 inhibitor approved, effectively inhibits HIV-1 entry into cells and is well endured (Woollard and Kanmogne, 2015). MVC was investigated as a potential topical pre-exposure prophylaxis (PrEP) for HIV prevention. MVC has been determined to be well endured orally and topically (McGowan et al., 2022). Plerixafor, the first CXCR4 antagonist, was licensed for non-Hodgkin and multiple myeloma in 2008. The mechanism of action of plerixafor may be related to the modulation of hematopoietic stem cells, blockade of X4 HIV-1 infection, increased circulating neutrophils, lymphocytes, and monocytes, decreased bone marrow-derived suppressor cells, and enhanced cytotoxic T-cell infiltration in tumors. However, it remains unproven whether plerixafor has an anti-HIV-1 impact (Wang et al., 2020). Salmeterol, a beta-2-adrenergic drug used to treat asthma, in combination with an anti-HIV-1 drug may cause patients to develop Cushing's syndrome. Thus, continued development and reuse of salmeterol in AIDS treatment is a potential strategy (Frias et al., 2016).
2.2 HIV-1 reverse transcriptase inhibitors
Inhibitors of HIV-1 reverse transcriptase are divided into nucleoside and non-nucleoside categories. Nucleoside reverse-transcriptase inhibitors (NRTIs), which compete with native nucleoside substrates and act as terminators of provirus DNA synthesis, and non-nucleoside reverse-transcriptase inhibitors (NNRTIs), which bind to hydrophobic pockets close to the site of reverse transcription activity, also perform an anti-retro translational function (shown in Figure 3) (Maga et al., 2010). In 1987, zidovudine (AZT), the first nucleoside reverse transcriptase inhibitor, was approved. Then followed didanosine, stavudine (d4T), lamivudine (3TC), and abacavir (ABC). In 2002, the drug adefovir dipivoxil (ADV) was licensed for oral administration. In advanced HIV disease, ADV is severely nephrotoxic and has no positive virological or immunological effects (Fisher et al., 2001). Despite therapy with ADV, HIV’s sensitivity to other medicines did not decrease (Miller et al., 2001). Emtricitabine (FTC) and tenofovir (PMPA/TFV) were approved in July 2003 and June 2008, respectively. Despite TFV efficacy in treating HIV-1 infection, there have been numerous reports of nephrotoxicity (Zhao et al., 2017). The approval dates for tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) are October 2001 and November 2016. TAF is a predecessor to TFV with significant long-term effectiveness and tolerance (Moorthy et al., 2020). Physiologically based pharmacokinetic (PBPK) modeling provides a mechanistic way to assess drug biodistribution by constructing a particular PBPK model that matches rats’ treatment with gold nanoparticles (AuNP), such as stavudine-AuNP. It was further confirmed that AuNP can significantly increase the drug concentration in cell and tissue species (Zazo et al., 2022). ABC was converted to carbohydrate triphosphate, 3TC was transformed to lamivudine triphosphate, and AZT was intracellularly phosphorylated. These metabolites compete with deoxyguanosine triphosphate and deoxycytidine triphosphate to integrate into HIV DNA. They cease DNA replication and block reverse transcription, exerting antiviral effects (Yoshida et al., 2021).
FIGURE 3
Nevirapine (1996) was the first non-nucleoside reverse transcriptase inhibitor approved, followed by delavirdine (discontinued) (Wang et al., 2019). After that, efavirenz (EFV), etravirine (ETR), rilpivirine (RPV), and apricitabine were commercialized. Ainuovirine (ANV) was approved for commercial use in China in 2021, reducing the neurotoxicity of the first-generation non-nucleoside reverse transcriptase inhibitor, EFV, and overcoming the decrease in efficacy of the second-generation non-nucleoside reverse transcriptase inhibitor at higher viral loads (Su et al., 2023).
HIV-1-positive patients’ ABC hypersensitivity is closely related to HLA-B*57:01 gene carriage (Faridi et al., 2020). Except for AZT, most antiretroviral medications (ARVs) correct neutropenia. Concerns remain, however, regarding their impact on neutrophil function, namely the risk of persistent neutrophil activation. Neutrophil activation may predispose HIV-positive persons to chronic inflammatory disorders. The importance of platelets in the immune response to infection is becoming increasingly apparent. Even with antiretroviral medication, these cells contain HIV viruses and enhance viral transmission (ART). However, HIV-infected patients are typically characterized by thrombocytopenia, prolonged platelet activation, and dysfunction that may occur, exacerbating persistent immunological activation and an inflammatory vascular environment and increasing the risk of complications such as cardiovascular disease (CVD). Clinical trials have linked medications such as ABC and DRV to an increased CVD risk (Madzime et al., 2021).
Parents who are infected with HIV have the potential to transfer the infection to their offspring. The condition being referred to is commonly known as congenital infection. The use of ETR is generally well-tolerated and considered to be safe. The study found that children between the ages of 2 and 6 demonstrated higher viral effectiveness rates than children under the age of 2 (MacBrayne et al., 2021). Confirming ABC’s safety as a baseline medicine in neonates is still pending in HIV-1-positive individuals. While no adverse events were seen, a few neonates displayed symptoms consistent with anaphylaxis. In the context of drug administration to newborns, it has been observed that the utilization of ABC requires a reduction in the dosage of liquid ABC. However, additional researches are needed to evaluate the viability of employing solid formulations of neonatal ABC. These researches should specifically focus on assessing the feasibility of utilizing fixed-dose antiretroviral combinations (FDC), as these combinations have the potential to enhance the accessibility of comprehensive antiretroviral therapy (cART) for infants and children globally (Bekker et al., 2021). In order to overcome the constraints imposed by current anti-HIV medications, researchers are presently engaged in developing hydrophobic pharmaceuticals utilizing nanocarrier. Compared to conventional pharmaceuticals, it has been observed that anionic lipid vectors based on ETR exhibit much more efficacy in managing HIV-1 infection within HIV-infected cell lines. A notable improvement in the therapeutic index and pharmacokinetic properties accompanies this higher effectiveness. Therefore, utilizing a nanocarrier-based medication system with high hydrophobicity can serve as a targeted multi-site drug delivery system, offering therapeutic advantages in effectively eliminating HIV/AIDS infection (Rojekar et al., 2021).
2.3 Protease inhibitors
The HIV-1 protease consists of 99 amino acids that cleave the progenitors of the Gag and Gag-Pol polymers to produce mature, active proteins. The majority of HIV protease inhibitors are metabolized in the liver by the cytochrome P450 (CYP450) enzyme, which has a solid potential to inhibit the drug-metabolizing enzyme CYP450 3A4 (CYP3A4) (Dash and Boix, 2021), hence inhibiting HIV reproduction in vivo and attaining antiviral effects. Saquinavir, the first HIV protease inhibitor of the first generation, was launched in 1995 (Pereira and Vale, 2022). It was followed by ritonavir (RTV), indinavir (IDV), and nelfinavir (NFV). Amprenavir (APV) was also published in 1995, and fosamprenavir (FPV) is a promedication of APV (Arvieux and Tribut, 2005). Since then, lopinavir (LPV), atazanavir (ATV), tipranavir (TPV), and darunavir (DRV) have all been developed.
IDV was initially licensed as a autonomous drug. Physicians commonly prescribe RTV pharmacokinetic ‘boost’ in clinical practice to eliminate dietary restrictions, reduce pills, and make twice-daily dosing easier (Boyd, 2007). Liposomal nanoparticles (LNPs) specifically target CD4 and deliver IDV to CD4+-HIV host cells have been developed. Added polyethylene glycol to LNPs reduces peptide immunoprecipitation and boosts anti-HIV activity (Endsley and Ho, 2012). For pediatric, adolescent, adult, and gestational HIV infections, NFV is accessible. However, long-term drug resistance to NFV may result in mutations in HIV-1 D30N (Perry et al., 2005). In chemotherapy-resistant cancer cells, via endoplasmic reticulum/non-folding protein accentuating responses, NFV produces selective mitochondrial-independent cell death. In addition, NCV has antimicrobial properties against malaria, tuberculosis (TB), and SARS (Bruning et al., 2010), as well as echinococcosis (Liu et al., 2022), which has been demonstrated to ameliorate lung pathology generated by SARS-CoV-2 in animal models (Foo et al., 2022). DRV and LPV are suggested for resistance infections (Wong-Sam et al., 2022). ATV is an HIV protease inhibitor that decreases bilirubin binding competitively, and serum bilirubin levels are inversely related to cardiovascular risk. Compared to individuals receiving DRV, which did not elevate serum bilirubin, patients using ARV had a lower risk of cardiovascular disease and increased survival, which shows that creating a persistent rise in serum bilirubin could be a potential treatment strategy for reducing cardiovascular risk (Li et al., 2020). DRV combined with two NRTIs resulted in long-lasting viral suppression, even in patients with prior NRTI resistance. In addition, there is no risk of drug resistance, and a more prominent position in public health methods should be considered (Paton et al., 2021; Paton et al., 2022). TPV causes temporary and typically asymptomatic rises in blood aminotransferase levels, a rare cause of clinically apparent acute liver damage. During TPV therapy, patients with chronic hepatitis B or C exacerbations may experience liver injury (King and Acosta, 2006). The HIV-1 M46I mutation generated a structural kinetic shift that diminished the saquinavir effect without altering the protein’s activity. These findings could be exploited to build inhibitors of HIV-1 proteases resistant to durgs (Rana et al., 2022). Muscular tiredness, weakness, and pain caused by ATV, ERV, and RTV result from their disruption of the calcium homeostasis of the skeletal and cardiac sarcoplasmic reticulum (SR) muscles (Alomar et al., 2021). Computer analysis was performed on 14 HIV-1 proteinases (HPS/002, HPS/004, HPS/006, HPS/007, HPS/008, HPS/009, HPS/010, HPS/011, HPS/012, HPS/013, HPS/014, HPS/020, and HPS/024) to identify potential new antiviral drugs. The IC50/HIV-1 inhibition percentage, drug metabolism, and safety profiles of HPS/002 and HPS/004 indicate their suitability for clinical trials and research (Okafor et al., 2022).
2.4 Integrase inhibitors
Integrase (IN) is necessary for lentiviral replication (Jurado and Engelman, 2013), and integrase inhibitors assist HIV in integrating genetic information-carrying DNA into host DNA, which is typically carried by the virus but absent from host cells. Integrase inhibitors are divided into IN-chain-transfer inhibitors (INSTIs) and IN-binding inhibitors (INBIs). The former binds to the enzyme’s catalytic core domain, inhibiting its binding to dsDNA and the latter attaches to the IN’s foreign pocket, preventing conformational adjustments essential for a chain reaction (shown in Figure 4) (Trivedi et al., 2020). Common integrase inhibitors include raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and bictegravir (BIC) (Martin et al., 2021), all belonging to the INSTI class. Cabotegravir sodium (CAB), a member of the class of integrin-chain-transfer inhibitors (Engelman and Engelman, 2021), has shown remarkable safety in preventing HIV-1 in women in 2020 (Delany-Moretlwe et al., 2022). Long-acting cabotegravir injections (CAB LA) may be more effective during (PrEP) (Clement et al., 2020).
FIGURE 4
2.5 Viral capsid inhibitor
HIV-1 patients resistant to multiple antiretroviral drugs have few treatment alternatives. In August 2022, lenacapavir (Sunlenca) became commercially available (Mushtaq and Kazi, 2023). It is a weakly acidic indazole derivative with low water solubility and permeability. Lenacapavir selectively binds to the interface of the two hexameric subunits of the HIV-1 capsid, resulting in the development or inhibition of the immature HIV-1 capsid, interfering with capsid-mediated HIV-1 nuclear uptake, viral assembly and release, and capsid core formation during the HIV-1 life cycle (Dzinamarira et al., 2023). Furthermore, it demonstrated strong antiviral effectiveness in phase 1b research. Individuals with HIV-1 infection and multidrug resistance who received lenacapavir experienced a significant reduction in viral load compared to those who got a placebo at baseline (Segal-Maurer et al., 2022). Lenacapavir lacked cross-resistance to existing antiretroviral classes and was administered orally daily or weekly (Dvory-Sobol et al., 2022) or subcutaneously twice a year as an injectable solution (Paik, 2022).
GSK878 is a newly described HIV-1 inhibitor that binds to a mature capsid (CA) hexamer in a pocket identified initially as a binding site for the CA inhibitor PF-74 (Wang et al., 2023). GSK878 is involved in early (pre-integration) and late (post-integration) HIV-1 replication and is associated with altered stability in the HIV-1 CA core (Gillis et al., 2023).
2.6 Other antiviral drugs
Foscarnet sodium is tolerant to multiple viruses, including HIV, HSV, and HBV (Zeichner, 1998). As a polymerase inhibitor, it interferes with RNA synthesis and viral replication. Patients undergoing bisphosphonate drug demonstrated a decrease in plasma HIV-1 load (Devianne-Garrigue et al., 1998). In macrophages infected with antiretroviral medicines (AZT, EFV, IDV and ENF), type III interferons (IFNs) inhibit HIV-like viruses and improve anti-HIV action synergistically. IFNs can inhibit various strains, including the AZT-resistant virus (A012) and the reverse transcriptase inhibitor-resistant (TC49). Theoretically, IFNs can trigger multiple potent anti-HIV cytokines. These results strengthen the case that IFNs could be utilized to treat HIV infection (Wang et al., 2017). Moreover, resveratrol 3,4′,5-trihydroxydiphenylene may function as a potential HIV-1 therapeutic agent by reactivating SIRT1 closure induced by HIV infection and reducing the activity of the Tat protein of HIV, thereby preventing the activation of other HIV proteins and HIV spread to other cells. In addition, resveratrol inhibits several HIV cell enzymes in their reproduction. It also increases the development of enzymes necessary for activating nucleoside analogs. Therefore, resveratrol overcame past viral resistance to dihydroxy myosides (Zhang et al., 2009). Mupirocin, also known as pseudotumor A, is an isoleucine-tRNA synthetase that inhibits bacterial expression and is generated by fluorescent pseudomonas. It has been demonstrated to be efficient against various gram-positive and gram-negative bacteria (Mirza et al., 2020). As the only treatment proven to eradicate nasal obstruction in HIV-infected patients, S. aureus nasal carriage in HIV-infected patients was abolished after a few weeks (Martin et al., 1999), although the risk of relapse remained unchanged (Martin et al., 1999; Gordon et al., 2010).
3 Anti-HIV-1 combination drugs
3.1 Pharmacokinetic enhancer combination
Cobicistat (COBI) is an efficient inhibitor of the non-retroviral CYP3A4 enzyme, and when taken with antiretroviral drugs metabolized via the CYP3A4 route, it improves antiretroviral function. In addition to CYP3A4, COBI possesses inhibitory activity against CYP3A5, CYP2C9, CYP2D6, and the P-glycoprotein transporter (P-gp) (Dash and Boix, 2021). COBI is more acceptable, bioequivalent, and non-inferior to RTV (Deeks, 2014). It is non-inferior and bioequivalent to RTV and minimizes undesirable effects such as drug-drug interactions, fat degeneration, and hyperlipidemia. COBI has no anti-HIV action; hence, resistance to COBI as an add-on therapy is less of a concern (Putcharoen et al., 2015). Approved in August 2012, EVG/COBI/FTC/TDF (Stribild) is the first monotherapy regimen containing integrase inhibitors for HIV-1 infection (Olin et al., 2012). It consists of the integrated-chain-transfer inhibitor of HIV-1 (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir (150 mg/150 mg/200 mg/300 mg) for once-daily treatment of HIV-1 infection in adults who have failed antiretroviral therapy. EVG/COBI/FTC/TDF is one of the preferred regimens (Perry, 2014) suggested for initial treatment and has a higher probability of achieving postexposure prophylaxis (PEP) than a multi-tablet regimen (MTR) (Malinverni et al., 2021). In November 2015, EVG/COBI/FTC/TAF (Genvoya) was approved and recommended as a first-line treatment. Regardless of the difficulty of employing cobicistat and other enhancers and the absence of a genetic barrier as high as with second-generation integrase inhibitors, EVG/COBI/FTC/TAF was a success in this population, with virtually no viral failure and no resistance mutations (Perez Stachowski et al., 2022). EVG/COBI/FTC/TAF is well tolerated, maintains HBV and HIV suppression, and improves proteinuria in HIV/HBV-coinfected individuals (Huang et al., 2021). Even the resistance mutation M184V/I did not affect the efficacy of E/EVG/COBI/FTC/TAF (Perez-Valero et al., 2021). In 2015, DRV/COBI (Rezolsta) became the first fixed-dose combination of protease inhibitors to be licensed for the treatment of HIV. Using DRV/COBI on healthy volunteers proved COBI’s efficacy and demonstrated the drug’s safety and efficacy in phase III research (Navarro and Curran, 2016). During pregnancy, increased CYP3A activity may contribute to the metabolism of DRV and COBI. Thus, regular DRV/COBI therapy during pregnancy may increase the risk of virological failure and perinatal transmission (Momper et al., 2021). However, it also suppresses viral load effectively (Dash and Boix, 2021.). ATV/COBI (Evotaz) was licensed for commercial usage in January 2015 and was efficacious and well tolerated in individuals with extensive HIV infection (Gallant et al., 2017). Randomized clinical trials demonstrated that ATV/c and ATV/RTV have equal efficacy and safety, long half-lives (Elliot et al., 2017), low rates of virological failure, and no ATV-resistant mutations. According to experts, ATV/COBI represents a new chance to expand the approach of switching to dual therapy to lower the danger of long-term harmful consequences (Antunes, 2017). The standard dosage of ATV/COBI during pregnancy may increase the likelihood of virological failure and perinatal transmission (Momper et al., 2022). COBI/DRV/FTC/TAF (Symtuza) 150/800/200/10 mg is the first single-pill daily regimen (STR) (Rashbaum et al., 2019) based on the protease inhibitor (PI) to treat HIV-1-infected adults and adolescents. It was introduced in September 2017. It combines the advantages of a genetic barrier to protease inhibition, pharmacokinetic enhancers, and nucleoside reverse transcriptase inhibitors (Deeks, 2018). COBI, DRV, FTC, and TAF revealed excellent renal and skeletal safety and CNS tolerance (Squillace et al., 2018).
3.2 Antiretroviral combinations
Using ABT-containing regimens (ABT/DTG or ABT/TDF/3TC) for HIV PEP demonstrates superior safety, tolerability, and adherence to non-ABT antiretroviral drug regimens (Nie et al., 2021). In addition, the novel dual-agent combination of ABT and LPV/RTV exhibited substantial dose-response correlations and could be evaluated in a broader patient group (Zhang et al., 2016). FTC is a member of the class of antiretroviral medicines that work when taken with TAF and TDF (Mayer et al., 2020). FTC/TDF and FTC/TAF were approved in 2004 and 2015. FTC/TAF increased renal safety compared to FTC/TDF but did not exhibit FTC/TDF lipid-lowering effects (Mesplede, 2021). Combined therapy with FTC and TDF effectively reduced HIV infection in male users, high-risk heterosexuals, and injectable drug users with shared devices. Drug resistance was infrequent but strongly associated with treatment duration and adherence. Combined therapy with FTC and TDF enhanced bone mineral density and kidney safety biomarkers. In addition, the concentrations of total cholesterol, high-density lipoprotein, and low-density lipoprotein dropped faster, consistent with their recognized lipid-lowering actions. Thus, the selection of preventive medicines before HIV exposure varies between populations (Ogbuagu et al., 2021; Fernando, 2018). FTC/RPV/TDF (Eviplera) was released in August 2011. Due to adverse effects involving the central nervous system and metabolic abnormalities, individuals were moved from an NNRTI-based regimen containing EFV, FTC, and TDF to Eviplera, and lipid distribution and CVR improved. Simultaneously, immunovirological control remained steady (Perez-Hernandez et al., 2014). The DTG/ABC/3TC triple therapy entered the market in August 2014 with everyday dosing, no augmentation, and a larger genetic resistance barrier (Christensen and Tan, 2022). ABC/DTG/3TC was launched in the same year. When switching regimens were evaluated for people with stable HIV-1 infection, switching to ABC/DTG/3TC was related to enhanced virologic effectiveness and safety (Trottier et al., 2017). DTG/RPV was introduced in November 2017 as the first dual antiretroviral STR (Dowers et al., 2018) to be used for maintenance therapy of HIV-1 infection. It was effective and safe for patients with viral suppression for at least 6 months (Sun et al., 2018). In February 2018, a single-agent regimen containing the integrase inhibitor BIC (Sax et al., 2021) was introduced as a secure and more practical option for patients already resistant to NRTIs (Stellbrink et al., 2020), without detectable emergent resistance or proximal tubular disease, and with improved gastrointestinal tolerability (Orkin et al., 2020b). Use during pregnancy was associated with the lowest composite of poor pregnancy outcomes and infant death (Lockman et al., 2021). AZT/3TC/NVP and EFV/3TC/TDF were introduced simultaneously.
Until June 2018, an EFV-based regimen was the optimal first-line treatment for HIV-1 infection, according to the World Health Organization (WHO). Because of side effects concerns, the combination of DTG and low-dose EVF was considered the first-line treatment for HIV-1 in areas with limited resources. The WHO suggested DTG in combination with two NRTIs for second-line therapy of HIV-1 infection (Calmy et al., 2020; Paton et al., 2021), and AZT replaced TFD as the first-line NRTI (Group et al., 2019). AZT is used with other anti-HIV drugs, including 3TC and ABC, to treat HIV infection. Effective in treating HIV-1-infected patients, particularly those with substantial NRTI resistance, is the combination of AZT, DTG, and NRTIs. As a second-line treatment, TDF is as effective as AZT. DOR/3TC/TDF was introduced in August 2018 and demonstrated no further resistance to EFV/FTC/TDF between weeks 48 and 96. It had fewer patients with sudden viral resistance and remained constant at week 96. Moreover, DOR/3TC/TDF showed improved safety, fewer neuropsychiatric side events, and a better lipid profile than the 2006-marketed EFV/FTC/TDF regimen (Orkin et al., 2021). In April 2019, DTG/3TC, a combination drug routinely used in clinical settings, was approved for commercial use. It efficiently maintained virological suppression (Llibre et al., 2023). It had a strong resistance gene barrier (Cahn et al., 2022), making it a viable first and subsequent therapy choice for HIV-1-infected individuals who are unknown or believed to be resistant to INSTIs or 3TC (Scott, 2020). CAB plus long-acting RPV, introduced in December 2019, can be used as an alternative to daily oral therapy for HIV-1-positive patients and may improve the ease of treatment, adherence, and quality of life for HIV-1-infected patients by reducing treatment frequency (up to six doses per year) (Overton et al., 2021). CAB/RPV therapy was non-inferior to oral DTG/ABC/3TC therapy in sustaining HIV-1 suppression, and patients reported improved satisfaction with treatment (Orkin et al., 2020a). BIC/FTC/TAF (Biktarvy) is approved for use in HIV-1 infection in both treatment-naive and treatment-experienced individuals after a series of successful phase III trials, and its clinical efficacy has also been confirmed (Peters and Iwuji, 2023). In March 2020, a CAB/RPV (Cabenuva) including a second-generation INSTI and NNRT was introduced, administered intramuscularly monthly (Howe et al., 2021), and viral failure was infrequent (Cutrell et al., 2021). In January 2023, ANV/TDF/3TC (ACC008) was approved, with a favorable safety profile (Huang et al., 2023).
4 Concluding remarks and future perspectives
To date, we have been able to better comprehend and analyze the genesis of DRM and its potential for transmission using next-generation sequencing (NGS) by evaluating HIV sequencing, drug susceptibility tests, and clinical data in a public database (Blassel et al., 2021). According to the literature, next-generation sequencing (NGS) techniques provide efficient methods by rapidly obtaining thousands to millions of short nucleotide sequences (Van Laethem et al., 2015). In addition, Sanger sequencing (SS) can be utilized to discover HIV resistance (DR), and pool-tagged pyrophosphate sequencing (TPP) can be used to identify low-abundance drug resistance variants at a reduced cost (Ji et al., 2013). Currently, most AIDS treatments are antiviral (inhibition of viral replication), and combination therapy is frequently employed to prevent drug resistance. HIV vaccine research has brought fresh insights into AIDS clinical prevention in recent years. RNA-based technologies are among the top candidates for gene therapies where they can be stably expressed for long-term HIV-1 suppression. Advances in gene and drug delivery strategies and improvements to non-coding RNA stability and antiviral properties will cooperatively drive progress in improving drug therapy and engineering HIV-1-resistant cells (Chen et al., 2023). The reported case series of HIV-cured patients in 2022 revealed that hematopoietic stem cell transplantation prevented HIV entrance into cells (Hsu et al., 2023). Thus, developing protective vaccines remains a top goal for HIV/AIDS epidemic control. Regardless of past immunogenic data, the ALVAC-gp120 regimen did not protect South African volunteers from HIV-1 infection (Gray et al., 2021). Although largely tolerated, immunization schedules at high mRNA dosages are challenging (Zhang et al., 2021). Based on RV144’s moderate efficiency, South African researchers launched a follow-up study with a modified vaccine design, the ALVAC-HIV vector, and the gp120 protein enhancer (Clade C strain) (Pitisuttithum and Marovich, 2020). A successful vaccination would considerably enhance and minimize health service strain. It is undeniable that vaccination has historically been the most cost-effective public health intervention required to eradicate infectious illnesses, with widespread diffusion and longevity (Dispinseri et al., 2022), and the problem of treatment resistance is still the key to healing for people with HIV-1. Thus, rational use of antiviral drugs, rational preexposure prophylaxis, and avoidance of the emergence of resistant mutations in the population and even the development of new resistant strains is essential. Using second-generation sequencing and other technologies to rationally predict the development of population resistance while attaching importance to vaccine development is critical to curing HIV-1-positive patients and preventing HIV infection.
Statements
Author contributions
YP: Writing–original draft. YZ: Writing–original draft. DW: Writing–original draft. JC: Software, Writing–original draft. Z-SC: Supervision, Writing–review and editing. FP: Funding acquisition, Supervision, Writing–review and editing. ZL: Funding acquisition, Supervision, Writing–review and editing.
Funding
The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by grants from the Shandong Provincial Natural Science Foundation of China (ZR2019MC059), the Youth Natural Science Foundation of Shandong Province (ZR2021QH367), and the Public Sponsored Domestic Visiting Program of Weifang Medical University (No. 20237-11).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AlaofiA. L. (2022). The Glu143 residue might play a significant role in T20 peptide binding to HIV-1 receptor gp41: an in silico study. Molecules27 (12), 3936. 10.3390/molecules27123936
2
AlomarF. A.TianC.DashP. K.McMillanJ. M.GendelmanH. E.GorantlaS.et al (2021). Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca(2+) homeostasis in skeletal muscles. Antivir. Res.187, 104975. 10.1016/j.antiviral.2020.104975
3
AntunesF. (2017). Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Rev. Anti Infect. Ther.15 (6), 569–576. 10.1080/14787210.2017.1323634
4
AquaroS.BorrajoA.PellegrinoM.SvicherV. (2020). Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages. Virulence11 (1), 400–413. 10.1080/21505594.2020.1760443
5
ArvieuxC.TributO. (2005). Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. medications65 (5), 633–659. 10.2165/00003495-200565050-00005
6
BbosaN.KaleebuP.SsemwangaD. (2019). HIV subtype diversity worldwide. Curr. Opin. HIV AIDS14 (3), 153–160. 10.1097/COH.0000000000000534
7
BekkerA.DecloedtE. H.SladeG.CottonM. F.RabieH.CresseyT. R. (2021). Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). Clin. Infect. Dis.72 (11), 2032–2034. 10.1093/cid/ciaa1026
8
BettikerR. L.KorenD. E.JacobsonJ. M. (2018). Ibalizumab. Curr. Opin. HIV AIDS13 (4), 354–358. 10.1097/COH.0000000000000473
9
BlairH. A. (2020). Ibalizumab: a review in multidrug-resistant HIV-1 infection. medications80 (2), 189–196. 10.1007/s40265-020-01258-3
10
BlasselL.ZhukovaA.Villabona-ArenasC. J.AtkinsK. E.HueS.GascuelO. (2021). Drug resistance mutations in HIV: new bioinformatics approaches and challenges. Curr. Opin. Virol.51, 56–64. 10.1016/j.coviro.2021.09.009
11
BoydM. (2007). Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?Expert Opin. Pharmacother.8 (7), 957–964. 10.1517/14656566.8.7.957
12
BruningA.GingelmaierA.FrieseK.MylonasI. (2010). New prospects for nelfinavir in non-HIV-related diseases. Curr. Mol. Pharmacol.3 (2), 91–97. 10.2174/1874467211003020091
13
CahnP.Sierra MaderoJ.ArribasJ. R.AntinoriA.OrtizR.ClarkeA. E.et al (2022). Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS36 (1), 39–48. 10.1097/QAD.0000000000003070
14
CalmyA.Tovar SanchezT.KouanfackC.Mpoudi-EtameM.LeroyS.PerrineauS.et al (2020). Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV7 (10), e677–e687. 10.1016/s2352-3018(20)30238-1
15
Cano-OrtizL.LueddeT.MunkC. (2023). HIV-1 restriction by SERINC5. Med. Microbiol. Immunol.212 (2), 133–140. 10.1007/s00430-022-00732-x
16
CarterE. P.AngC. G.ChaikenI. M. (2023). Peptide triazole inhibitors of HIV-1: hijackers of env metastability. Curr. Protein Pept. Sci.24 (1), 59–77. 10.2174/1389203723666220610120927
17
ChenM. J.GatignolA.ScarboroughR. J. (2023). The discovery and development of RNA-based therapies for treatment of HIV-1 infection. Expert Opin. Medicat. Discov.18 (2), 163–179. 10.1080/17460441.2022.2117296
18
ChongH.YaoX.ZhangC.CaiL.CuiS.WangY.et al (2012). Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One7 (3), e32599. 10.1371/journal.pone.0032599
19
ChristensenB. L.TanD. H. (2022). An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. Expert Opin. Pharmacother.23 (4), 439–446. 10.1080/14656566.2022.2029409
20
ClementM. E.KofronR.LandovitzR. J. (2020). Long-acting injectable cabotegravir for the prevention of HIV infection. Curr. Opin. HIV AIDS15 (1), 19–26. 10.1097/COH.0000000000000597
21
CutrellA. G.SchapiroJ. M.PernoC. F.KuritzkesD. R.QuerciaR.PatelP.et al (2021). Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS35 (9), 1333–1342. 10.1097/QAD.0000000000002883
22
DashP. K.BoixV. (2021). Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns. AIDS35 (8), 1301–1303. 10.1097/QAD.0000000000002886
23
DeeksE. D. (2014). Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. medications74 (2), 195–206. 10.1007/s40265-013-0160-x
24
DeeksE. D. (2018). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. medications78 (10), 1013–1024. 10.1007/s40265-018-0934-2
25
Delany-MoretlweS.HughesJ. P.BockP.OumaS. G.HunidzariraP.KalonjiD.et al (2022). Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet399 (10337), 1779–1789. 10.1016/S0140-6736(22)00538-4
26
Devianne-GarrigueI.PellegrinI.DenisiR.DuponM.RagnaudJ. M.BarbeauP.et al (1998). Foscarnet decreases HIV-1 plasma load. J. Acquir Immune Defic. Syndr. Hum. Retrovirol18 (1), 46–50. 10.1097/00042560-199805010-00007
27
DispinseriS.TolazziM.ScarlattiG. (2022). The path towards an HIV vaccine. New Microbiol.45 (2), 99–103. 10.1016/j.pbj.2017.06.002
28
DowersE.ZamoraF.BarakatL. A.OgbuaguO. (2018). Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV AIDS (Auckl)10, 215–224. 10.2147/HIV.S157855
29
Dvory-SobolH.ShaikN.CallebautC.RheeM. S. (2022). Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr. Opin. HIV AIDS17 (1), 15–21. 10.1097/COH.0000000000000713
30
DzinamariraT.AlmehmadiM.AlsaiariA. A.AllahyaniM.AljuaidA.AlsharifA.et al (2023). Highlights on the development, related patents, and prospects of lenacapavir: the first-in-class HIV-1 capsid inhibitor for the treatment of multi-drug-resistant HIV-1 infection. Med. Kaunas.59 (6), 1041. 10.3390/medicina59061041
31
ElliotE. R.AmaraA.PaganiN.ElseL.MoyleG.SchoolmeestersA.et al (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. J. Antimicrob. Chemother.72 (7), 2035–2041. 10.1093/jac/dkx108
32
EllwangerJ. H.Kulmann-LealB.KaminskiV. L.RodriguesA. G.BragatteM. A. S.ChiesJ. A. B. (2020). Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res.286, 198040. 10.1016/j.virusres.2020.198040
33
EndsleyA. N.HoR. J. (2012). Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J. Acquir Immune Defic. Syndr.61 (4), 417–424. 10.1097/QAI.0b013e3182653c1f
34
EngelmanK. D.EngelmanA. N. (2021). Long-acting cabotegravir for HIV/AIDS prophylaxis. Biochemistry60 (22), 1731–1740. 10.1021/acs.biochem.1c00157
35
FaridiR. M.PatelS.Dharmani-KhanP.GillJ.BerkaN.KhanF. M. (2020). Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients. Microbiol. Immunol.64 (3), 210–218. 10.1111/1348-0421.12769
36
FauciA. S.PantaleoG.StanleyS.WeissmanD. (1996). Immunopathogenic mechanisms of HIV infection. Ann. Intern Med.124 (7), 654–663. 10.7326/0003-4819-124-7-199604010-00006
37
FernandoD. (2018). HIV preexposure prophylaxis. Am. J. Public Health108 (12), e27. 10.2105/AJPH.2018.304757
38
FigueiraT. N.DominguesM. M.IllienF.Cadima-CoutoI.TodorovskiT.AndreuD.et al (2020). Enfuvirtide-protoporphyrin IX dual-loaded liposomes: in vitro evidence of synergy against HIV-1 entry into cells. ACS Infect. Dis.6 (2), 224–236. 10.1021/acsinfecdis.9b00285
39
FisherE. J.ChalonerK.CohnD. L.GrantL. B.AlstonB.BrosgartC. L.et al (2001). The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS15 (13), 1695–1700. 10.1097/00002030-200109070-00013
40
FooC. S.AbdelnabiR.KapteinS. J. F.ZhangX.Ter HorstS.MolsR.et al (2022). HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antivir. Res.202, 105311. 10.1016/j.antiviral.2022.105311
41
FrankelA. D.YoungJ. A. (1998). HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem.67, 1–25. 10.1146/annurev.biochem.67.1.1
42
FriasA.OrtizA.SotoM.MunozF.ChaconC. (2016). Cushing syndrome in a HIV patient using inhaled steroids. Report of one case. Rev. Med. Chil.144 (7), 931–936. 10.4067/S0034-98872016000700016
43
GallantJ.MoyleG.BerenguerJ.ShalitP.CaoH.LiuY. P.et al (2017). Atazanavir plus cobicistat: week 48 and week 144 subgroup analyses of a phase 3, randomized, double-blind, active-controlled trial. Curr. HIV Res.15 (3), 216–224. 10.2174/1570162X14666161021102728
44
GillisE. P.ParcellaK.BowsherM.CookJ. H.IwuagwuC.NaiduB. N.et al (2023). Potent long-acting inhibitors targeting the HIV-1 capsid based on a versatile quinazolin-4-one scaffold. J. Med. Chem.66 (3), 1941–1954. 10.1021/acs.jmedchem.2c01732
45
GordonR. J.ChezN.JiaH.ZellerB.SobieszczykM.BrennanC.et al (2010). The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals. J. Acquir Immune Defic. Syndr.55 (4), 466–472. 10.1097/QAI.0b013e3181ec2a68
46
GrayG. E.BekkerL. G.LaherF.MalahlehaM.AllenM.MoodieZ.et al (2021). Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med.384 (12), 1089–1100. 10.1056/NEJMoa2031499
47
GroupN. A. S.KouanfackC.Mpoudi-EtameM.Omgba BassegaP.Eymard-DuvernayS.LeroyS.et al (2019). Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N. Engl. J. Med.381 (9), 816–826. 10.1056/NEJMoa1904340
48
HoweZ. W.NormanS.LuekenA. F.HuesgenE.FarmerE. K.JarrellK.et al (2021). Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic. Pharmacotherapy41 (8), 686–699. 10.1002/phar.2605
49
HsuJ.Van BesienK.GlesbyM. J.PahwaS.ColettiA.WarshawM. G.et al (2023). HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell.186 (6), 1115–1126.e8. 10.1016/j.cell.2023.02.030
50
HuangL.LeiJ.YangY.MaT.LinH.CaoB.et al (2023). Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for ainuovirine, lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects. Clin. Pharmacol. Medicat. Dev.10.1002/cpdd.1309
51
HuangY. S.ChengC. Y.LiouB. H.LuP. L.ChengS. H.LeeY. T.et al (2021). Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment in HIV/HBV-coinfected patients. J. Acquir Immune Defic. Syndr.86 (4), 473–481. 10.1097/QAI.0000000000002589
52
JiH.LiangB.LiY.Van DomselaarG.GrahamM.TylerS.et al (2013). Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. J. Virol. Methods187 (2), 314–320. 10.1016/j.jviromet.2012.10.018
53
JuradoK. A.EngelmanA. (2013). Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors. Expert Rev. Mol. Med.15, e14. 10.1017/erm.2013.15
54
KaplanA.DeHaanE.MaltzC. (2021). Reactivation of hepatitis B after ibalizumab therapy for multidrug-resistant human immunodeficiency virus. ACG Case Rep. J.8 (5), e00594. 10.14309/crj.0000000000000594
55
KingJ.R.AcostaE.P. (2006). Tipranavir. Clin. Pharmacokinet.45 (7), 665–682. 10.2165/00003088-200645070-00003
56
LiM.ChanW. W.ZuckerS. D. (2020). Association between atazanavir-induced hyperbilirubinemia and cardiovascular disease in patients infected with HIV. J. Am. Heart Assoc.9 (19), e016310. 10.1161/JAHA.120.016310
57
LiuZ.GuoX.GuoA.ZhangS.ZouY.WangY.et al (2022). HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein. EBioMedicine82, 104177. 10.1016/j.ebiom.2022.104177
58
LlibreJ. M.BritesC.ChengC. Y.OsiyemiO.GaleraC.HocquelouxL.et al (2023). Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin. Infect. Dis.76 (4), 720–729. 10.1093/cid/ciac130
59
LockmanS.BrummelS. S.ZiembaL.Stranix-ChibandaL.McCarthyK.ColettiA.et al (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet397 (10281), 1276–1292. 10.1016/S0140-6736(21)00314-7
60
LuD. Y.WuH. Y.YarlaN. S.XuB.DingJ.LuT. R. (2018). HAART in HIV/AIDS treatments: future trends. Infect. Disord. Medicat. Targets18 (1), 15–22. 10.2174/1871526517666170505122800
61
LyuT.YueY.HsiehE.HanY.ZhuT.SongX.et al (2020). HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study. BMC Infect. Dis.20 (1), 66. 10.1186/s12879-020-4785-6
62
MacBrayneC. E.RutsteinR. M.WizniaA. A.GrahamB.AlveroC. G.FairlieL.et al (2021). Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS35 (9), 1413–1421. 10.1097/QAD.0000000000002902
63
MadzimeM.RossouwT. M.TheronA. J.AndersonR.SteelH. C. (2021). Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Front. Immunol.12, 634386. 10.3389/fimmu.2021.634386
64
MagaG.RadiM.GerardM. A.BottaM.EnnifarE. (2010). HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate. Viruses2 (4), 880–899. 10.3390/v2040880
65
MalinverniS.BedoretF.BartiauxM.GillesC.De WitS.LiboisA. (2021). Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims. Sex. Transm. Infect.97 (5), 329–333. 10.1136/sextrans-2020-054714
66
MartinC.GraciasS.CharpentierC.DescampsD.Le HingratQ.PlantierJ. C.et al (2021). HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. J. Antimicrob. Chemother.76 (9), 2306–2309. 10.1093/jac/dkab196
67
MartinJ. N.Perdreau-RemingtonF.KartalijaM.PasiO. G.WebbM.GerberdingJ. L.et al (1999). A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J. Infect. Dis.180 (3), 896–899. 10.1086/314949
68
MayerK. H.MolinaJ. M.ThompsonM. A.AndersonP. L.MounzerK. C.De WetJ. J.et al (2020). Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet396 (10246), 239–254. 10.1016/S0140-6736(20)31065-5
69
McGowanI. M.ChawkiS.HendrixC. W.AntonP. A.MarzinkeM. A.BrandR. M.et al (2022). A randomized, open-label, crossover phase 1 safety and pharmacokinetic study of oral maraviroc and maraviroc 1% gel (the CHARM-03 study). AIDS Res. Hum. Retroviruses38 (4), 269–278. 10.1089/AID.2021.0096
70
MespledeT. (2021). Evaluating the combination of emtricitabine/tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. Expert Opin. Pharmacother.22 (10), 1245–1251. 10.1080/14656566.2021.1902504
71
MillerM. D.MargotN. A.LamyP. D.FullerM. D.AntonK. E.MulatoA. S.et al (2001). Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir Immune Defic. Syndr.27 (5), 450–458. 10.1097/00126334-200108150-00005
72
MirzaM. U.SaadabadiA.VanmeertM.Salo-AhenO. M. H.AbdullahI.ClaesS.et al (2020). Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach. Eur. J. Pharm. Sci.155, 105537. 10.1016/j.ejps.2020.105537
73
MomperJ. D.WangJ.StekA.ShapiroD. E.ScottG. B.PaulM. E.et al (2021). Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV. Aids35 (8), 1191–1199. 10.1097/qad.0000000000002857
74
MomperJ. D.WangJ.StekA.ShapiroD. E.PowisK. M.PaulM. E.et al (2022). Pharmacokinetics of atazanavir boosted with cobicistat in pregnant and postpartum women with HIV. J. Acquir Immune Defic. Syndr.89 (3), 303–309. 10.1097/QAI.0000000000002856
75
MonteiroA.YuK. O. A.HicarM. D. (2021). Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond. Curr. HIV Res.19 (6), 465–475. 10.2174/1570162X19666210908115231
76
MoorthyG. S.Lalley-ChareczkoL.KoenigH. C.ZuppaA. F. (2020). Tenofovir urine assay to monitor adherence to HIV pre-exposure prophylaxis. Curr. Clin. Pharmacol.15 (2), 102–104. 10.2174/1574884714666191111125348
77
MushtaqA.KaziF. (2023). Lenacapavir: a new treatment of resistant HIV-1 infections. Lancet Infect. Dis.23 (3), 286. 10.1016/S1473-3099(23)00075-0
78
NavarroJ.CurranA. (2016). Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV AIDS (Auckl)8, 175–182. 10.2147/HIV.S56158
79
NieJ.SunF.HeX.LiuJ.WangM.LiC.et al (2021). Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China. Infect. Dis. Ther.10 (4), 2611–2623. 10.1007/s40121-021-00540-5
80
OgbuaguO.RuaneP. J.PodzamczerD.SalazarL. C.HenryK.AsmuthD. M.et al (2021). Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV8 (7), e397–e407. 10.1016/S2352-3018(21)00071-0
81
OkaforS. N.AngsantikulP.AhmedH. (2022). Discovery of novel HIV protease inhibitors using modern computational techniques. Int. J. Mol. Sci.23 (20), 12149. 10.3390/ijms232012149
82
OlinJ. L.SpoonerL. M.KlibanovO. M. (2012). Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann. Pharmacother.46 (12), 1671–1677. 10.1345/aph.1R468
83
OrkinC.ArastehK.Gorgolas Hernandez-MoraM.PokrovskyV.OvertonE. T.GirardP. M.et al (2020a). Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med.382 (12), 1124–1135. 10.1056/NEJMoa1909512
84
OrkinC.DeJesusE.SaxP. E.ArribasJ. R.GuptaS. K.MartorellC.et al (2020b). Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV7 (6), e389–e400. 10.1016/S2352-3018(20)30099-0
85
OrkinC.SquiresK. E.MolinaJ. M.SaxP. E.SussmannO.LinG.et al (2021). Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin. Infect. Dis.73 (1), 33–42. 10.1093/cid/ciaa822
86
OvertonE. T.RichmondG.RizzardiniG.JaegerH.OrrellC.NagimovaF.et al (2021). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet396 (10267), 1994–2005. 10.1016/S0140-6736(20)32666-0
87
PaikJ. (2022). Lenacapavir: first approval. medications82 (14), 1499–1504. 10.1007/s40265-022-01786-0
88
PatonN. I.MusaaziJ.KityoC.WalimbwaS.HoppeA.BalyegisawaA.et al (2021). Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N. Engl. J. Med.385 (4), 330–341. 10.1056/NEJMoa2101609
89
PatonN. I.MusaaziJ.KityoC.WalimbwaS.HoppeA.BalyegisawaA.et al (2022). Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV9 (6), e381–e393. 10.1016/S2352-3018(22)00092-3
90
PedroK. D.HendersonA. J.AgostoL. M. (2019). Mechanisms of HIV-1 cell-to-cell transmission and the establishment of the latent reservoir. Virus Res.265, 115–121. 10.1016/j.virusres.2019.03.014
91
PereiraM.ValeN. (2022). Saquinavir: from HIV to COVID-19 and cancer treatment. Biomolecules12 (7), 944. 10.3390/biom12070944
92
Perez StachowskiJ.Rial CresteloD.Moreno ZamoraA.CabelloN.RyanP.Espinosa AguileraN.et al (2022). Use of tenofovir alafenamide/emtricitabine/elvitegravir-cobicistat in HIV-naive patients with advanced disease: GENIS study. J. Clin. Med.11 (17), 4994. 10.3390/jcm11174994
93
Perez-HernandezI. A.PalaciosR.MayorgaM.Gonzalez-DomenechC. M.CastanoM.RiveroA.et al (2014). Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114. J. Int. AIDS Soc.17 (43), 19795. 10.7448/IAS.17.4.19795
94
Perez-ValeroI.LlibreJ. M.CastagnaA.PulidoF.MolinaJ. M.EsserS.et al (2021). Switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in adults with HIV and M184V/I mutation. J. Acquir Immune Defic. Syndr.86 (4), 490–495. 10.1097/QAI.0000000000002595
95
PerryC. M. (2014). Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults. medications74 (1), 75–97. 10.1007/s40265-013-0158-4
96
PerryC. M.FramptonJ. E.McCormackP. L.SiddiquiM. A.CvetkovicR. S. (2005). Nelfinavir: a review of its use in the management of HIV infection. medications65 (15), 2209–2244. 10.2165/00003495-200565150-00015
97
PetersE.IwujiA. C. (2023). Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: a scoping review. Antivir. Ther.28 (1), 13596535231159030. 10.1177/13596535231159030
98
PitisuttithumP.MarovichM. A. (2020). Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Expert Rev. Vaccines19 (2), 133–142. 10.1080/14760584.2020.1718497
99
PutcharoenO.DoT.AvihingsanonA.RuxrungthamK. (2015). Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther9, 5763–5769. 10.2147/dddt.S63989
100
RanaN.SinghA. K.ShuaibM.GuptaS.HabiballahM. M.AlkhananiM. F.et al (2022). Drug resistance mechanism of M46I-Mutation-Induced saquinavir resistance in HIV-1 protease using molecular dynamics simulation and binding energy calculation. Viruses14 (4), 697. 10.3390/v14040697
101
RashbaumB.SpinnerC. D.McDonaldC.MussiniC.JezorwskiJ.LuoD.et al (2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive patients with HIV-1: subgroup analyses of the phase 3 AMBER study. HIV Res. Clin. Pract.20 (1), 24–33. 10.1080/15284336.2019.1608714
102
ReinA. (2019). RNA packaging in HIV. Trends Microbiol.27 (8), 715–723. 10.1016/j.tim.2019.04.003
103
RichardJ.PrevostJ.BourassaC.BrassardN.BoutinM.BenlarbiM.et al (2023). Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. Cell. Chem. Biol.30 (5), 540–552.e6. 10.1016/j.chembiol.2023.03.003
104
Riviere-CazauxC.CornellJ.ShenY.ZhouM. (2022). The role of CCR5 in HIV-associated neurocognitive disorders. Heliyon8 (7), e09950. 10.1016/j.heliyon.2022.e09950
105
RojasV. K.ParkI. W. (2019). Role of the ubiquitin proteasome system (UPS) in the HIV-1 life cycle. Int. J. Mol. Sci.20 (12), 2984. 10.3390/ijms20122984
106
Rojas-CelisV.Valiente-EcheverríaF.Soto-RifoR.Toro-AscuyD. (2019). New challenges of HIV-1 infection: how HIV-1 attacks and resides in the central nervous system. Cells8 (10), 1245. 10.3390/cells8101245
107
RojekarS.Fotooh AbadiL.PaiR.MahajanK.KulkarniS.VaviaP. R. (2021). Multi-organ targeting of HIV-1 viral reservoirs with etravirine loaded nanostructured lipid carrier: an in-vivo proof of concept. Eur. J. Pharm. Sci.164, 105916. 10.1016/j.ejps.2021.105916
108
RubioA. A.Filsinger InterranteM. V.BellB. N.BrownC. L.BruunT. U. J.LaBrancheC. C.et al (2021). A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2-neutralizing activity. J. Virol.95 (15), e0235020. 10.1128/JVI.02350-20
109
SaxP. E.RockstrohJ. K.LuetkemeyerA. F.YazdanpanahY.WardD.TrottierB.et al (2021). Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin. Infect. Dis.73 (2), e485–e493. 10.1093/cid/ciaa988
110
ScottL. J. (2020). Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection. medications80 (1), 61–72. 10.1007/s40265-019-01247-1
111
Segal-MaurerS.DeJesusE.StellbrinkH. J.CastagnaA.RichmondG. J.SinclairG. I.et al (2022). Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med.386 (19), 1793–1803. 10.1056/NEJMoa2115542
112
SiegertS.SchnierleP.SchnierleB. S. (2006). Novel anti-viral therapy: drugs that block HIV entry at different target sites. Mini Rev. Med. Chem.6 (5), 557–562. 10.2174/138955706776876267
113
SquillaceN.BozziG.ColellaE.GoriA.BanderaA. (2018). Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Medicat. Des. Devel Ther.12, 3635–3643. 10.2147/DDDT.S147493
114
StellbrinkH. J.LazzarinA.WoolleyI.LlibreJ. M. (2020). The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med.21 (1), 3–16. 10.1111/hiv.12833
115
SuB.GaoG.WangM.LuY.LiL.ChenC.et al (2023). Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet Regional Health - West. Pac.36, 100769. 10.1016/j.lanwpc.2023.100769
116
SunH. Y.ChangS. Y.HungC. C. (2018). Dolutegravir-rilpivirine coformulation. Curr. Opin. HIV AIDS13 (4), 320–325. 10.1097/COH.0000000000000466
117
SurveD. H.JirwankarY. B.DigheV. D.JindalA. B. (2020). Long-acting efavirenz and HIV-1 fusion inhibitor peptide Co-loaded polymer-lipid hybrid nanoparticles: statistical optimization, cellular uptake, and in vivo biodistribution. Mol. Pharm.17 (10), 3990–4003. 10.1021/acs.molpharmaceut.0c00773
118
TanQ.ZhuY.LiJ.ChenZ.HanG. W.KufarevaI.et al (2013). Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science341 (6152), 1387–1390. 10.1126/science.1241475
119
TrivediJ.MahajanD.JaffeR. J.AcharyaA.MitraD.ByrareddyS. N. (2020). Recent advances in the development of integrase inhibitors for HIV treatment. Curr. HIV/AIDS Rep.17 (1), 63–75. 10.1007/s11904-019-00480-3
120
TrottierB.LakeJ. E.LogueK.BrinsonC.SantiagoL.BrennanC.et al (2017). Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir. Ther.22 (4), 295–305. 10.3851/IMP3166
121
UsamiY.WuY.GottlingerH. G. (2015). SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature526 (7572), 218–223. 10.1038/nature15400
122
Van LaethemK.TheysK.VandammeA. M. (2015). HIV-1 genotypic medication resistance testing: digging deep, reaching wide?Curr. Opin. Virol.14, 16–23. 10.1016/j.coviro.2015.06.001
123
WangC.HuangH.MallonK.ValeraL.ParcellaK.CockettM. I.et al (2023). Antiviral properties of HIV-1 capsid inhibitor GSK878. Antimicrob. Agents Chemother.67 (5), e0169422. 10.1128/aac.01694-22
124
WangJ.TannousB. A.PoznanskyM. C.ChenH. (2020). CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent. Pharmacol. Res.159, 105010. 10.1016/j.phrs.2020.105010
125
WangT.KadowJ. F.MeanwellN. A. (2021). Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. Med. Chem. Res.30 (11), 1955–1980. 10.1007/s00044-021-02787-6
126
WangX.WangH.LiuM. Q.LiJ. L.ZhouR. H.ZhouY.et al (2017). IFN-Λ inhibits drug-resistant HIV infection of macrophages. Front. Immunol.8, 210. 10.3389/fimmu.2017.00210
127
WangY.De ClercqE.LiG. (2019). Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin. Medicat. Metab. Toxicol.15 (10), 813–829. 10.1080/17425255.2019.1673367
128
Wong-SamA.WangY. F.KnellerD. W.KovalevskyA. Y.GhoshA. K.HarrisonR. W.et al (2022). HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics. J. Mol. Graph Model.117, 108315. 10.1016/j.jmgm.2022.108315
129
WoollardS. M.KanmogneG. D. (2015). Maraviroc: a review of its use in HIV infection and beyond. Medicat. Des. Devel Ther.9, 5447–5468. 10.2147/DDDT.S90580
130
YeruvaT.LeeC. H. (2022). Enzyme responsive delivery of anti-retroviral peptide via smart hydrogel. AAPS PharmSciTech23 (7), 234. 10.1208/s12249-022-02391-w
131
YoshidaY.HonmaM.KimuraY.AbeH. (2021). Structure, synthesis and inhibition mechanism of nucleoside analogues as HIV-1 reverse transcriptase inhibitors (NRTIs). ChemMedChem16 (5), 743–766. 10.1002/cmdc.202000695
132
ZazoH.ColinoC. I.Gutierrez-MillanC.CorderoA. A.BartneckM.LanaoJ. M. (2022). Physiologically based pharmacokinetic (PBPK) model of gold nanoparticle-based drug delivery system for stavudine biodistribution. Pharmaceutics14 (2), 406. 10.3390/pharmaceutics14020406
133
ZeichnerS. L. (1998). Foscarnet. Pediatr. Rev.19 (12), 399–400. 10.1542/pir.19-12-399a
134
ZhangC.ZhuR.CaoQ.YangX.HuangZ.AnJ.et al (2020). Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors. Exp. Biol. Med. (Maywood)245 (5), 477–485. 10.1177/1535370220901498
135
ZhangH.JinR.YaoC.ZhangT.WangM.XiaW.et al (2016). Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res. Ther.13, 8. 10.1186/s12981-016-0091-1
136
ZhangH.-S.ZhouY.WuM.-R.ZhouH.-S.XuF. (2009). Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci.85 (13), 484–489. 10.1016/j.lfs.2009.07.014
137
ZhangP.NarayananE.LiuQ.TsybovskyY.BoswellK.DingS.et al (2021). A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med.27 (12), 2234–2245. 10.1038/s41591-021-01574-5
138
ZhangZ.HouW.ChenS. (2022). Updates on CRISPR-based gene editing in HIV-1/AIDS therapy. Virol. Sin.37 (1), 1–10. 10.1016/j.virs.2022.01.017
139
ZhaoX.SunK.LanZ.SongW.ChengL.ChiW.et al (2017). Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. Sci. Rep.7, 46344. 10.1038/srep46344
Summary
Keywords
anti-HIV-1 drugs, monotherapy, combination therapy, HIV/AIDS treatment, predict HIV mutations, SERINC3, SERINC5
Citation
Peng Y, Zong Y, Wang D, Chen J, Chen Z-S, Peng F and Liu Z (2023) Current drugs for HIV-1: from challenges to potential in HIV/AIDS. Front. Pharmacol. 14:1294966. doi: 10.3389/fphar.2023.1294966
Received
15 September 2023
Accepted
11 October 2023
Published
26 October 2023
Volume
14 - 2023
Edited by
Wei Zhao, Chengdu Medical College, China
Reviewed by
Yan-Mei Jiao, Fifth Medical Center of the PLA General Hospital, China
Bin Wang, Qingdao University, China
Updates
Copyright
© 2023 Peng, Zong, Wang, Chen, Chen, Peng and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhe-Sheng Chen, chenz@stjohns.edu; Fujun Peng, pengfujun@wfmc.edu.cn; Zhijun Liu, zhijun.liu@wfmc.edu.cn
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.